IL10 and neoplasm: Considering that IL-10 could enhance proliferation of MM cells, and reduce Adriamycin-induced cell death, we hypothesized that CuB-mediated inhibition of the STAT3 pathway might synergistically enhance the anti-tumor activity of Adriamycin.